GnRH-gemcitabine conjugates for the treatment of androgen-independent prostate cancer : pharmacokinetic enhancements combined with targeted drug delivery

Loading...
Thumbnail Image

Authors

Karampelas, Theodoros
Argyros, Orestis
Sayyad, Nisar
Spyridaki, Katerina
Pappas, Charalampos
Morgan, Kevin
Kolios, George
Millar, Robert P.
Liapakis, George
Tzakos, Andreas G.

Journal Title

Journal ISSN

Volume Title

Publisher

American Chemical Society

Abstract

Gemcitabine, a drug with established efficacy against a number of solid tumors, has therapeutic limitations due to its rapid metabolic inactivation. The aim of this study was the development of an innovative strategy to produce a metabolically stable analogue of gemcitabine that could also be selectively delivered to prostate cancer (CaP) cells based on cell surface expression of the Gonadotropin Releasing Hormone- Receptor (GnRH-R). The synthesis and evaluation of conjugated molecules, consisting of gemcitabine linked to a GnRH agonist, is presented along with results in androgen-independent prostate cancer models. NMR and ligand binding assays were employed to verify conservation of microenvironments responsible for binding of novel GnRH-gemcitabine conjugates to the GnRH-R. In vitro cytotoxicity, cellular uptake and metabolite formation of the conjugates were examined in CaP cell lines. Selected conjugates were efficacious in the in vitro assays with one of them, namely GSG, displaying high antiproliferative activity in CaP cell lines along with significant metabolic and pharmacokinetic advantages in comparison to gemcitabine. Finally, treatment of GnRH-R positive xenografted mice with GSG, showed a significant advantage in tumor growth inhibition when compared to gemcitabine.

Description

Keywords

Gemcitabine, Rapid metabolic inactivation, Gonadotropin-releasing hormone-receptor (GnRH-R)

Sustainable Development Goals

Citation

Karampelas, T, Argyros, O, Sayyad, N, Spyridaki, K, Pappas, C, Morgan, K, Kolios, G, Millar, RP, Liapakis, G, Tzakos, AG, Fokas, D & Tamvakopoulos, C 2014, 'GnRH-gemcitabine conjugates for the treatment of androgen-independent prostate cancer : pharmacokinetic enhancements combined with targeted drug delivery', Bioconjugate Chemistry, vol. 25, no. 4, pp. 813-823.